Here, we describe the establishment of the first organoid for metastatic tRCC with a common fusion (PRCC-TFE3) and describe the HTS process with a goal of discovering effective drugs in vitro that could be further evaluated in the clinic. This evidence concerns the gene TFE3 and renal cell carcinoma associated with Xp11.2 translocations/TFE3 gene fusions.